5-Aza-2'-Deoxycytidine (5-Aza-dC, Decitabine) Inhibits Collagen Type I and III Expression in TGF-β1-Treated Equine Endometrial Fibroblasts.
Authors: Alpoim-Moreira Joana, Szóstek-Mioduchowska Anna, Słyszewska Magda, Rebordão Maria Rosa, Skarzynski Dariusz J, Ferreira-Dias Graça
Journal: Animals : an open access journal from MDPI
Summary
# Editorial Summary Endometrosis represents a significant fertility challenge in mares, driven by pathological accumulation of type I and III collagen within the endometrium; this Portuguese-led research team investigated whether epigenetic mechanisms—specifically DNA methylation—underpin this fibrotic process and whether modulating these mechanisms might offer therapeutic potential. Using in vitro models of equine endometrial fibroblasts, the researchers exposed cells to transforming growth factor-β1 (TGF-β1), a key driver of fibrosis that triggers myofibroblast differentiation and collagen synthesis, then treated them with 5-aza-2'-deoxycytidine (5-aza-dC), a drug that inhibits DNA methylation. The results demonstrated that whilst TGF-β1 upregulated DNA methyltransferase 3A transcripts and collagen secretion, administration of 5-aza-dC successfully reduced both collagen type I and III transcripts and their secretion in the culture medium, though it did not suppress α-smooth muscle actin expression (the myofibroblast marker). These findings suggest that DNA methylation dysregulation contributes to equine endometrial fibrogenesis, potentially opening new avenues for targeted anti-fibrotic treatments beyond conventional approaches, though further in vivo validation will be necessary before clinical application in breeding mares. For practitioners managing endometrosis cases, this epigenetic perspective may eventually complement existing diagnostic and therapeutic strategies, particularly if pharmacological DNA methyltransferase inhibition proves tolerable and effective in clinical settings.
Read the full abstract on PubMed
Practical Takeaways
- •Endometrosis involves epigenetic regulation of collagen deposition; DNA methylation inhibitors like decitabine may offer a novel therapeutic approach to reduce excessive fibrosis in mare endometrium
- •This in vitro work provides foundational evidence that epigenetic modifiers could potentially be developed as treatments for equine endometrial fibrosis, though clinical validation is needed
- •The differential effect on collagen versus α-SMA expression suggests targeted epigenetic approaches may selectively reduce fibrotic collagen without affecting all myofibroblast markers
Key Findings
- •TGF-β1 upregulated DNMT3A transcripts and collagen secretion in equine endometrial fibroblasts
- •5-aza-dC (decitabine) decreased collagen type I and III transcripts and secretion in TGF-β1-treated fibroblasts
- •5-aza-dC did not reduce α-SMA transcripts despite reducing collagen expression
- •Epigenetic mechanisms appear to regulate collagen synthesis during equine endometrial fibrogenesis